7,163 results match your criteria: "Bullous Pemphigoid"

Macrophages in inflammatory skin diseases and skin tumors.

Front Immunol

December 2024

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Macrophages, as specialized, long-lasting phagocytic cells of the innate immune system, have garnered increasing attention due to their wide distribution and various functions. The skin, being the largest immune organ in the human body, presents an intriguing landscape for macrophage research, particularly regarding their roles in inflammatory skin diseases and skin tumors. In this review, we compile the latest research on macrophages in conditions such as atopic dermatitis, psoriasis, systemic sclerosis, systemic lupus erythematosus, rosacea, bullous pemphigoid, melanoma and cutaneous T-cell lymphoma.

View Article and Find Full Text PDF

We present the case of a 36-year-old paraplegic woman with a history of spinal cord injury who developed a generalized blistering rash, later diagnosed as bullous pemphigoid (BP). During her hospitalization, she was treated with prednisone and rituximab infusions, transitioning to maintenance therapy with topical steroids, doxycycline, and nicotinamide. A year later, she presented with concerns about a BP flare on her feet.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing the immune system's ability to target cancer cells. However, ICIs can lead to immune-related adverse events (irAEs), including dermatologic manifestations such as bullous pemphigoid (BP).

Objective: To evaluate the efficacy and safety of omalizumab and other biologics in the treatment of ICI-induced refractory bullous pemphigoid and to derive a strategy for selecting biologic treatments for this condition.

View Article and Find Full Text PDF

Background: Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events. Dupilumab has emerged as an alternative therapeutical option of BP patients.

Objectives: To evaluate the efficacy of dupilumab monotherapy and the combination with medium/low-dose corticosteroids for BP treatment.

View Article and Find Full Text PDF

Background: Robust and well-defined data collection is important when using electronic patient-reported outcome measures (ePROMs) in clinical studies. Questions have been raised as to whether older age may be a barrier to data collection due to patients' unfamiliarity with electronic devices. Older adults may also have underlying health conditions that affect their ability to fill out patient-reported outcome measures (PROMs) on electronic devices.

View Article and Find Full Text PDF

Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230.

Front Immunol

December 2024

Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy.

Background: Bullous pemphigoid (BP) and mucous membrane pemphigoid (MMP) are rare autoimmune blistering disorders characterized by autoantibodies (autoAbs) targeting dermo-epidermal junction components such as BP180 and BP230. The differential diagnosis, based on both the time of appearance and the extension of cutaneous and/or mucosal lesions, is crucial to distinguish these diseases for improving therapy outcomes and delineating the correct prognosis; however, in some cases, it can be challenging. In addition, negative results obtained by commercially available enzyme-linked immunosorbent assays (ELISAs) with BP and MMP sera, especially from patients with ocular involvement, often delay diagnosis and treatment, leading to a greater risk of poor outcomes.

View Article and Find Full Text PDF

Comorbid diseases in bullous pemphigoid: A population-based case-control study.

J Dermatol

December 2024

Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.

Bullous pemphigoid (BP) is the most prevalent autoimmune blistering disorder, triggered by autoantibodies targeting hemidesmosome components. It is associated with substantial morbidity and increased mortality. No studies comprehensively evaluate all comorbidities before and after diagnosing patients with BP.

View Article and Find Full Text PDF

Bullous pemphigoid (BP) is a chronic autoimmune disorder characterized by subepidermal blister formation, primarily affecting elderly individuals. While BP has been associated with malignancies, the exact nature of this relationship remains unclear. We report the case of a 72-year-old man who presented with pruritic cutaneous lesions, including tense vesicles and bullae and was diagnosed with BP.

View Article and Find Full Text PDF

Milia within resolving bullous pemphigoid lesions.

Dermatol Online J

August 2024

Department of Dermatology, King Abdullah Medical Complex, Jeddah, Saudi Arabia.

Article Synopsis
View Article and Find Full Text PDF
Article Synopsis
  • Autoimmune blistering disorders (AIBD) are conditions where the body produces auto-antibodies against adhesion proteins in the skin, detectable through direct immunofluorescence (DIF) or blood tests like ELISA.
  • This study aimed to assess how well the results from a new multivariant ELISA method agreed with AIBD diagnoses established from clinical assessments, histopathology, and DIF.
  • The results showed a good overall correlation between ELISA and diagnoses, particularly strong in pemphigus vulgaris, but with variable agreement levels in other types of AIBD and limitations due to the retrospective nature of the study.
View Article and Find Full Text PDF
Article Synopsis
  • Pemphigus foliaceus (PF) and bullous pemphigoid (BP) are two different autoimmune skin diseases caused by autoantibodies affecting skin adhesion proteins.
  • The occurrence of both PF and BP in a single patient is uncommon, as demonstrated in the case of a 72-year-old male who exhibited symptoms of both conditions.
  • Treatment for this patient included immunoglobulin, intravenous dexamethasone, oral triamcinolone, and minocycline, leading to significant improvement and emphasizing the need for precise diagnosis and effective treatment.
View Article and Find Full Text PDF

Probing into functional decline among bullous pemphigoid patients.

J Eur Acad Dermatol Venereol

December 2024

Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.

View Article and Find Full Text PDF
Article Synopsis
  • The development of lichen planus (LP) from radiation is very rare, with only 14 cases noted, and malignancy linked to LP is uncommon, primarily seen in oral forms.
  • This report discusses a unique case of erosive cutaneous LP that transformed into malignancy at a site previously treated with radiation, highlighting the need for careful evaluation and monitoring in similar cases.
View Article and Find Full Text PDF

Aim: Increasing observational studies are revealing a positive correlation between body mass index (BMI) and the risk of Immune-mediated and Inflammatory Skin Diseases (IMID), however the causal relationship is not yet definite.

Objective: The aim of the study was to conduct a two-sample Mendelian randomization (TSMR) to explore the potential causality between BMI, and IMID and biomarkers.

Methods: The summary statistics for BMI (n = 322,154), at genome-wide significant level, were derived from the Genetic Investigation of Anthropometric Traits consortium (GIANT).

View Article and Find Full Text PDF

Bullous pemphigoid (BP) is a rare autoimmune blistering disease that primarily affects elderly individuals. Based on the Bullous Pemphigoid Disease Area Index (BPDAI) severity assessment, immunosuppressive drugs are recommended for severe cases that fall within the more than moderate classes. Sarcopenia, which is characterized by decreased skeletal muscle mass and function in elderly patients, is a progressive and widespread skeletal muscle disease.

View Article and Find Full Text PDF

Melanoma, with increasing annual incidence worldwide, is one of the deadliest cutaneous malignancies often treated with immunotherapy, which has led to commonly encountered immune-related adverse events (irAEs) including bullous pemphigoid (BP). The relation between an individual's HLA inheritance and risk in development of BP is well studied. The development of BP as an irAE in melanoma patients receiving immunotherapy is also well reported and considered to be related to the expression of BP180 in malignant melanoma.

View Article and Find Full Text PDF